Breast cancer subtype and survival among Indigenous American women in Peru
Lizeth I. Tamayo(University of Illinois Chicago), Laura Fejerman(University of California, San Francisco), Carlos A. Castañeda(Instituto Nacional de Enfermedades Neoplásicas), Sikai Song(San Francisco General Hospital), Garth H. Rauscher(University of Illinois Chicago), Henry Gómez(National Cancer Center), Jeannie Navarro Vásquez(Instituto Nacional de Enfermedades Neoplásicas), Sandro Casavilca‐Zambrano(Institute for Anthropological Research), Julio E. Abugattas(City of Hope), Daniel Cherry(University of San Diego), Mónica Calderón(Instituto Nacional de Enfermedades Neoplásicas), Jessica Ivonne Aramburu Palomino(Instituto Nacional de Enfermedades Neoplásicas), Tatiana Vidaurre(The University of Texas MD Anderson Cancer Center)
Cited by 17
Related Papers
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
|Journal of Clinical Oncology|2007|483